Press release
Multiple System Atrophy Market Expect to see more than 50% CAGR as Novel Therapies, AI Diagnostics, and FDA Fast Tracks Drive Growth | DelveInsight
Multiple System Atrophy Market Insight, Epidemiology and Market Forecast report
Key Insights on Multiple System Atrophy Market
*
Market Size Projection: As per DelveInsight's analysis, the total market size of Multiple System Atrophy in the 7MM is expected to grow from USD 44 million in 2025 to USD 1.8 billion by 2034, driven by a CAGR of more than 50% in major regions (US, EU4, UK, Japan).
*
Market Drivers: Key market drivers of Multiple System Atrophy include the launch of innovative therapies targeting alpha-synuclein, increased clinical trial activities, AI diagnostic breakthroughs, and robust investment in biomarker research and partnership strategies.
*
Multiple System Atrophy Epidemiology: The report provides the total Multiple System Atrophy potential pool of approximately 71000 prevalent cases in the 7MM, projected to rise with expanding awareness and improved detection protocols.
*
Key Companies: Leading Multiple System Atrophy companies include H. Lundbeck/Genmab (Amlenetug), Teva/MODAG (Emrusolmin), Theravance Biopharma (Ampreloxetine), Alterity Therapeutics (ATH434), AskBio, Ono Pharmaceuticals, AstraZeneca/Takeda, and others.
*
Pipeline Assets: Some of the key Multiple System Atrophy assets in the pipeline include Amlenetug (Lu AF82422), Emrusolmin (TEV-56286), ATH434, TAK-341/MEDI1341, and Ampreloxetine; most are in Phase II/III stages with breakthrough designations.
*
Recent Developments:
*
January 2025: Lantheus Holdings acquires Evergreen Theragnostics and plans acquisition of Life Molecular Imaging, advancing neurodegenerative diagnostics.
*
February 2025: Alterity Therapeutics reports positive Phase II results for ATH434; FDA grants Fast Track designation to ATH434 for MSA.
*
February 2025: The FDA Fast Track designation for Amlenetug; progress in alpha-synuclein inhibitor clinical trials.
*
April 2025: Tiziana Life initiates dosing in Phase IIa study, securing FDA approval for clinical protocol.
*
May 2025: FDA Fast Track designation for ATH434 (Alterity Therapeutics).
*
September 2025: Teva's Emrusolmin receives FDA Fast Track designation for Multiple System Atrophy treatment; AskBio completes Phase I trial enrollment for AB-1005 gene therapy in MSA-P.
*
August-September 2025: Major clinical trial updates: CYPRESS Phase III ampereplexotine trial (Theravance) fully enrolled; Amlenetug Phase III study ongoing.
*
Ongoing: NKGen Biotech receives FDA expanded access for NK cell therapy in MSA and other neurodegenerative diseases.
Gain exclusive access to projections, pipeline analysis, and executive insights @ Multiple System Atrophy Market Report [https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Multiple System Atrophy Market and Epidemiology Analysis
Multiple System Atrophy (MSA) is a complex, rapidly progressive neurodegenerative disorder with hallmark symptoms in movement and autonomic nervous system functioning. According to DelveInsight, the MSA market is poised for exponential growth, rising from USD 44 million in 2025 to USD 1.8 billion by 2034. North America (especially the US) dominates, hosting around ~60% of cases, followed by the EU4, the UK, and Japan.
According to DelveInsight's comprehensive Multiple System Atrophy Market Insight, Epidemiology and Market Forecast report [https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr], the market growth is driven by high unmet medical needs due to a lack of approved disease-modifying therapies, increased clinical research activities, advances in diagnostic imaging, biomarker identification, and the emergence of targeted therapies.
Furthermore, the epidemiological segmentation reveals two main subtypes: MSA-P (predominant Parkinsonism) and MSA-C (predominant cerebellar ataxia); notably, MSA-P is more prevalent except in Japan, where MSA-C dominates.
Multiple System Atrophy Competitive Landscape
Key companies and their Assets:
*
H. Lundbeck/Genmab: Amlenetug (Lu AF82422), monoclonal antibody targeting alpha-synuclein, Phase III; largest forecast revenue among emerging therapies, estimated at USD 795 million by 2034 in the 7MM.
*
Teva/MODAG: Emrusolmin (TEV-56286, Anle-138b), oral small molecule, Phase II, targeting toxic alpha-synuclein; Fast Track and Orphan Drug Designations.
*
Alterity Therapeutics: ATH434, targets iron dysregulation in alpha-synuclein aggregation, Phase II; Fast Track and Orphan Drug Designations.
*
Theravance Biopharma: Ampreloxetine, norepinephrine reuptake inhibitor for symptomatic nOH, enrolled in CYPRESS Phase III trial with ODD.
*
AskBio, Ono Pharmaceuticals, AstraZeneca/Takeda: advancing gene therapies and alpha-synuclein inhibitors.
Know which company has the competitive advantage in the Multiple System Atrophy Therapeutic Landscape @ Multiple System Atrophy Competitive Landscape Analysis [https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Multiple System Atrophy Market Drivers and Barriers
Some of Multiple System Atrophy Market Drivers include:
*
Unmet medical need: No approved disease-modifying therapies, high demand for novel interventions.
*
AI/Imaging breakthroughs: MSA-Atrophy Index and radiomics-based MRI models allow earlier and more accurate diagnosis, facilitating timely therapeutic intervention.
*
Emerging pipeline therapies: Robust clinical trial activity and regulatory support (ODD, Fast Track, SAKIGAKE) accelerating time to market and investment.
*
Patient advocacy and awareness: Earlier detection is increasing as advocacy and education efforts expand.
Some of Multiple System Atrophy Market Barriers include:
*
Diagnostic challenges: Overlap with Parkinsonian syndromes causes misdiagnosis and treatment delays.
*
Limited access: Geographic variability and high costs impede equitable therapy access, especially outside North America and Europe.
Dive deeper into the Multiple System Atrophy Market Drivers and Barriers @ Multiple System Atrophy Market Growth Analysis [https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Latest Key Opinion Leader Perspective on Multiple System Atrophy
KOLs across the US, Germany, and Japan highlight diagnosis complexity, limited symptom management options for autonomic and cerebellar dysfunction, and the critical role of emerging imaging (MIBG myocardial scintigraphy, MRI radiomics) in improving diagnostic accuracy. Physicians also emphasize the urgent need for novel, targeted, and accessible therapies to address high disease burden and unmet patient needs.
Know what other key opinion leaders are saying on Multiple System Atrophy Market and Patient Pool @ KOL Perspective on Multiple System Atrophy [https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
DelveInsight Analysis on Multiple System Atrophy Market and Patient Pool
DelveInsight analysts anticipate exponential market growth in MSA thanks to transformative clinical and regulatory milestones, ongoing pharma-academic collaborations, AI-powered diagnostic tools, and rising investment in pipeline therapies. Advancing precision diagnostics and the first disease-modifying treatments are expected to redefine the market landscape, benefiting patients and innovators alike.
Scope of the Report
*
Executive summary and descriptive overview of MSA: causes, symptoms, pathogenesis, and emerging therapies.
*
Comprehensive epidemiology segmentation and market forecasting for 7MM countries.
*
Future growth potential: diagnosis rate, disease progression, treatment guidelines.
*
Profiles of late-stage and pipeline therapies, including clinical trial details and strategic collaborations.
*
Country-wise accessibility, reimbursement, and cost-effectiveness assessment.
*
SWOT analysis, KOL perspectives, and market attractiveness evaluation.
*
Key questions addressed: historical/current/future market size, major contributors, disease risks, growth drivers, pipeline status, and patient acceptability of therapies.
Table of Contents
1. Key Insights
2. Executive Summary of Multiple System Atrophy
3. Competitive Intelligence Analysis for Multiple System Atrophy
4. Multiple System Atrophy Market Overview at a Glance
5. Multiple System Atrophy: Disease Background and Overview
6. Multiple System Atrophy Patient Journey
7. Multiple System Atrophy Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Multiple System Atrophy Unmet Needs
10. Key Endpoints of Multiple System Atrophy Treatment
11. Multiple System Atrophy Marketed Products
12. Multiple System Atrophy Emerging Therapies
13. Multiple System Atrophy: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Multiple System Atrophy
17. KOL Views
18. Multiple System Atrophy Market Drivers
19. Multiple System Atrophy Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=multiple-system-atrophy-market-expect-to-see-more-than-50-cagr-as-novel-therapies-ai-diagnostics-and-fda-fast-tracks-drive-growth-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Multiple System Atrophy Market Expect to see more than 50% CAGR as Novel Therapies, AI Diagnostics, and FDA Fast Tracks Drive Growth | DelveInsight here
News-ID: 4221699 • Views: …
More Releases from ABNewswire
Brand Apogee Launches Premium Gift Collection for America's Fastest-Growing Spor …
Brand Apogee has officially entered the retail market with a curated collection of high-quality gifts designed specifically for pickleball enthusiasts. Capitalizing on the explosive growth of America's fastest-growing sport, the new e-commerce brand serves millions of passionate players-particularly retirees who have embraced pickleball as a lifestyle-with premium products that celebrate their love for the game.
Brand Apogee is making its debut in the retail marketplace with strategic focus on one of…
Transforming Workspaces: Gras Lawn's Landscaping Services Improve Employee Well- …
Gras Lawn is helping local businesses improve employee well-being and productivity by transforming outdoor workspaces. Their professional landscaping services create cleaner, greener, and more inviting environments that support healthier, happier, and more efficient teams.
Deerfield Beach, FL Gras Lawn, a leading provider of commercial landscaping solutions in South Florida, has introduced new initiatives designed to help local businesses create healthier, more productive work environments. With a growing shift toward wellness-focused workplaces,…
Early Intervention in Aiea Supports School Readiness Through Step Ahead ABAs ABA …
Step Ahead ABA in Aiea provides early intervention programs that build school readiness for children with autism. Their personalized ABA therapy helps improve communication, behavior, and learning skills, giving families essential support for long-term success.
Aiea HI Step Ahead ABA reinforces its commitment to helping young children prepare for academic success through evidence-based early intervention programs rooted in Applied Behavior Analysis therapy. By focusing on foundational developmental skills, the organization provides…
Partnering with Families for Success A Gem of Joy ABA's Practitioner-Mediated AB …
A Gem of Joy ABA partners with Maryland families through practitioner-mediated ABA therapy, offering personalized support that empowers parents and helps children build meaningful skills, confidence, and long-term success.
Maryland - A Gem of Joy ABA is proud to announce the expansion of its practitioner-mediated ABA therapy model designed to provide families with a more collaborative, empowering approach to autism services. This family-centered method equips parents, caregivers, and loved ones with…
More Releases for Atrophy
Spinal Muscular Atrophy Market Trends That Will Shape the Next Decade: Insights …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Spinal Muscular Atrophy Market Size By 2025?
The market for spinal muscular atrophy has recently experienced substantial expansion; projections indicate a rise from a valuation of $3.53 billion in 2024 to $4 billion in 2025, reflecting a compounded annual growth rate totaling 13.3%. This acceleration…
Evolving Market Trends In The Spinal Muscular Atrophy Industry: Revolutionizing …
Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What Is the Expected Spinal Muscular Atrophy Market Size During the Forecast Period?
Recent years have witnessed a swift expansion of the spinal muscular atrophy market size. The market is projected to surge from $3.53 billion in 2024 to $4.01 billion in 2025, escalating at a compound annual growth rate (CAGR) of 13.5%. The…
Olivopontocerebellar Atrophy Market Size, Share & Trends [2025-2034]
The Olivopontocerebellar Atrophy Market Is Set To Grow At An Estimated CAGR Of 8.3% From 2025 To 2034, Rising From $1.3 Billion In 2024 To $2.8 Billion By 2034.
On April 16, 2025, Exactitude Consultancy., Ltd. released a research report offers a comprehensive examination of the various processes and materials used in the production of Olivopontocerebellar Atrophy market goods. The market study excludes key regions that are accelerating marketization. This section…
Geographic Atrophy Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Geographic Atrophy Pipeline Insight 2024" report provides comprehensive insights about 23+ companies and 25+ pipeline drugs in Geographic Atrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Geographic Atrophy Research. Learn more about…
Postmenopausal Vaginal Atrophy - Drug Pipeline Landscape, 2022
Vaginal Atrophy is a condition in which vagina gets drier and thinner and inflammation of the Vaginal walls may occur when the body has less estrogen. Vaginal Atrophy in which Vaginal refers to the vagina while Atrophy means wasting away or diminution occurs most often after menopause. For Many women, Vaginal Atrophy not only makes intercourse painful but also leads to distressing urinary symptoms
Read more about Postmenopausal Vaginal Atrophy's pipeline,…
Increasing cases of Spinal Muscular Atrophy will accelerate the Spinal Muscular …
Precision Business Insights published a research report on "Spinal Muscular Atrophy Management Market: By Type of Disease (Type-I, Type-II, Type-III, Type-IV), By Management (Gene Therapy, Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others), and Geography- Global/Region/Country Forecast to 2027", The Global Muscular Atrophy Management Market is anticipated to grow at considerable level during forecast period 2021-2027. Spinal Muscular Atrophy Management Market was valued at USD 1.3 Billion in 2020…
